Stockreport

SAB BIO Highlights Data in Multiple Presentations at EASD

SAB Biotherapeutics, Inc.  (SABS) 
PDF -As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought le [Read more]